trending Market Intelligence /marketintelligence/en/news-insights/trending/rYYTUM55RaiLFt6sdfcaaQ2 content esgSubNav
In This List

Ventura notches win against GSK in inhaler packaging case in UK court

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Ventura notches win against GSK in inhaler packaging case in UK court

Vectura Group PLC scored a win in its lawsuit against GlaxoSmithKline PLC relating to the packaging of a generic inhaler.

Chippenham, U.K.-based Ventura said the English High Court dismissed all of GlaxoSmithKline's claims involving the appearance and packaging of AirFluSal Forspiro, an inhaler launched in 2015 for patients with asthma and chronic obstructive pulmonary disease, or COPD.

Forspiro is a proprietary dry powder inhaler developed by Vectura, licensed to Novartis AG's generics unit Sandoz for use with AirFluSal.

In the lawsuit, GlaxoSmithKline accused Sandoz of using the same shades of purple to allegedly pass off AirFluSal Forspiro as connected to or same as the British drugmaker's Seretide Accuhaler product.

Following the court's decision, GlaxoSmithKline is considering next steps in the litigation, Reuters reported, citing a company spokesman.

The two companies are involved in a legal battle involving their respiratory products. In May, a jury at the U.S. District Court for the District of Delaware ruled that GlaxoSmithKline's sales of three Ellipta products infringed on Vectura's patent. The jury ordered GlaxoSmithKline to pay Ventura $89.7 million in damages.